Accès ouvert
2026
article
OpenAlex
Lycia Tramujas Vasconcellos Neumann, Simin Mahinrad, Erin Abner, Soo Borson et autres
Abstract The field of Alzheimer's disease and related dementias (AD/ADRD) is undergoing a transformative shift with a better understanding of disease biology, biomarker‐based diagnostics, and disease‐modifying therapies. Yet, these advancements risk exacerbating existing disparities in diagnosis and care. The 2024 Alzheimer's Association …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Stephen E. Hall, Leticia Garcia, Marie Stahmer, Percy Y. Griffin et autres
BACKGROUND: Roughly 7.2 million older Americans are living with Alzheimer's disease (AD). Research participation remains one of the largest barriers facing dementia research advancements. METHODS: TrialMatch is a dementia research awareness tool. TrialMatch consolidates research opportunities to serve as an open-access, centralized, …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sebastian Palmqvist, Heather Elizabeth Whitson, Laura A. Allen, Maria C. Carrillo et autres
BACKGROUND: In recent years, blood-based biomarkers (BBMs) have transformed the diagnostic landscape of Alzheimer's disease (AD), with some now approaching readiness for clinical implementation. This progress aligns with the growing importance of accurate early diagnostics and availability of anti-Aβ therapies for the …
se, us, es, nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Linda S. Brady, Simin Mahinrad, Rebecca M. Edelmayer, William Z. Potter et autres
Decades of research on biomarker identification and integration in Alzheimer's disease (AD) have helped to advance biologically driven disease models, disease subtypes, and disease-modifying treatments. Key lessons learned from AD biomarker development include the need for integration of new biological insights, investment …
us, de
(code pays fourni par la source)
Accès ouvert
2025
review
OpenAlex
Sarah C. Pahlke, Lara A Kahale, Simin Mahinrad, Bernardo Sousa‐Pinto et autres
BACKGROUND: This systematic review and meta-analysis aimed to assess the diagnostic test accuracy of blood-based biomarkers (BBMs) for detecting Alzheimer's disease (AD) pathology in cognitively impaired individuals in specialized care settings. The overarching goal is to inform the development of a clinical …
us, pt, nl, es, se, ca
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Bess E Frost, Hartmuth Christian Kolb, Alicia Algeciras‐Schimnich, Tobey J. Betthauser et autres
As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. The Fall 2024 Alzheimer's Association Research Roundtable convened experts from academia, industry, …
us, ch, br
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Inge M.W. Verberk, Mariam Gouda, Daniel Antwi‐Berko, Mardou van Leeuwenstijn et autres
INTRODUCTION: Blood-based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre-analytical stability requires scrutiny. This study assessed pre-analytical effects to inform a standardized sample handling protocol. METHODS: Assessed pre-analytical variations included collection tube type, hemolysis, centrifugation settings, centrifugation/storage delays, tube …
nl, se, be, us, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sebastian Palmqvist, Heather Elizabeth Whitson, Laura A. Allen, Marc Suárez‐Calvet et autres
OBJECTIVE AND SCOPE: A panel of clinicians, subject-matter experts, and guideline methodologists convened by the Alzheimer's Association conducted a systematic review and formulated evidence-based recommendations for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer's disease (AD) within specialized care …
se, us, es, nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Bess E Frost, James Benedict Rowe, Rufus Akinyemi, Jose Francisco Abisambra et autres
Recent years have seen major advances in tau-associated brain disorders through interdisciplinary research spanning molecular biology, neuroimaging, clinical trials, and therapeutic development. The Tau2024 Global Conference, hosted by the Alzheimer's Association, CurePSP, and Rainwater Charitable Foundation, showcased these efforts by bringing together …
us, gb, Nigéria, se, de, fr, in, ie, cl, es
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
David A. Wolk, Peter T. Nelson, Liana G. Apostolova, Konstantinos Arfanakis et autres
Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC). LATE-NC is a slowly progressive, amnestic clinical syndrome. Alternatively, when present with ADNC, LATE-NC is associated with a …
us, es, be, nl, gb, se
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Oskar Hansson, Heather Elizabeth Whitson, Rebecca M. Edelmayer, Laura A. Allen et autres
Abstract Background The rapid development of blood‐based biomarkers (BBMs) has improved Alzheimer’s disease (AD) diagnostics with some tests now potentially suitable for clinical use. This aligns with the clinical availability of anti‐Aβ immunotherapies for early symptomatic AD, where BBMs can help address …
se, us, es
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Charles Windon, Peggye Dilworth‐Anderson, Consuelo Hopkins Wilkins, María C. Carrillo et autres
Abstract Real‐World data platforms for Alzheimer’s Disease (AD) offer a unique opportunity to improve health equity through better understanding of health disparities and inclusivity in research, which is critical to translatability of research findings. AD research in the US and globally remains …
us
(code pays fourni par la source)